References
- Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2: 1281–1287, [PUBMED], [INFOTRIEVE]
- Citron M. L., Berry D. A., Cirrincione C., et al. Randomized trial of dose-dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Acute Leukemia Group B Trial 9741. J. Clin. Oncol. 2003; 21: 1431–1439, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wood W. W., Budman D., Korzun A., et al. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma. N. Engl. J. Med. 1994; 330: 1253–1259, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Piccart-Gebhart M. J. Mathematics and oncology: a match for life?. J. Clin. Oncol. 2003; 21: 1425–1428, [CROSSREF]
- Takimoto C. H., Rowinski E. K. Dose-intense paclitaxel: deja-vu all over again?. J. Clin. Oncol. 2003; 21: 2810–2814, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Citron M. L. Dose density in adjuvant therapy for breast cancer. Cancer Investig., 22: 556–569
- Thames H. A., Peters L. J., Withers H. R. Accelerated fractionation vs. hyperfractionation: rationale for several treatments per day. Int. J. Radiat. Oncol. Biol. Phys. 1983; 9: 127, [PUBMED], [INFOTRIEVE]
- Norton L., Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 1977; 61: 1307–1317, [PUBMED], [INFOTRIEVE]
- Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 1986; 70: 163–169, [PUBMED], [INFOTRIEVE]
- Hryniuk W., Frei E., Wright F. A. A single scale for comparing dose intensity of all chemotherapy regimens in breast cancer: summation dose intensity. J. Clin. Oncol. 1998; 16: 3137–3147, [PUBMED], [INFOTRIEVE]